Most recommended medicine for blood cancer

What is leukemia

Leukemia is a type of cancer that affects the white blood cells, which are responsible for protecting the body from disease and infection. Treatment for this cancer is complex, and each case is different, so the most recommended medicine for leukemia varies depending on the individual. Generally, treatment for leukemia involves chemotherapy, targeted therapy, stem cell transplantation, and some other therapies depending on the particular case.

Chemotherapeutic effects

Chemotherapy is commonly used to treat leukemia and involves putting drugs into the body through an intravenous (IV) line, or taken orally. Chemotherapy drugs aim to kill cancer cells while having minimal effects on healthy cells. In some cases, high-dose chemotherapy is used as a means to kill more of the cancer cells, and this is often followed by a stem cell transplant in order to restore healthy white blood cells.

Efficiency from targetted therapy

Targeted therapy is a type of medication that seeks to identify special structures on the surface of cancer cells, in order to specifically target and kill the cancer cells while sparing the healthy cells. Drugs such as tyrosine kinase inhibitors (TKIs) are used to block the signals that allow cancer cells to grow, spread and survive. These drugs can also be used in combination with chemotherapy or other standard treatments.

Stem cell transplantation as an ultimate cure

Stem cell transplantation is a treatment option for leukemia where the patient’s own stem cells, or those from a donor, are transplanted back into the body, with the goal of replacing the cancerous cells with healthy, functioning cells. This is a complex procedure and not all patients are able to receive a stem cell transplant, as it depends on a number of factors.

What is this type of injection?

Bendamustine Injection is an intravenous chemotherapeutic drug used to treat certain types of cancer. It was approved by the FDA in 2008 and its main active ingredient is Bendamustine hydrochloride, a synthetic alkylating agent. This injection is typically used to treat Hodgkin lymphoma, Indolent Non-Hodgkin lymphoma, and Chronic Lymphocytic Leukemia. It can also be used in combination with rituximab (Rituxan) to will treat Diffuse Large B-Cell Lymphoma.

Biochemical mode of action

Bendamustine works by damaging DNA, thus hindering the growth of cancer cells. This can also lead to the depletion of normal cells, but this is usually less than with other chemotherapy medications. Bendamustine is classified chemically as nitrogen mustard, and like other alkylating agents, induces the breakage of certain chemical bonds in the genetic material of cancer cells, resulting in the death of the cells.

Mode of its administration

Patients who can benefit from Bendamustine Injection must first undergo a consult with their health care team, as Bendamustine is not suitable for all types of cancer. Depending on the patient and the type of cancer, Bendamustine 100mg may be used alone or in combination with other chemotherapeutic agents. The medication is administered intravenously, typically at a dosage of 100–180 mg/m2 given over 30–60 minutes on days 1 and 2 of a 21-day treatment cycle. The number of cycles a patient receives will depend on the response to treatment and their overall health.

The effects which should be taken as a precaution

As with other chemotherapy drugs, Bendamustine can result in a variety of side effects and adverse events. Possible side effects may include nausea and vomiting, fatigue, low white blood cell count (neutropenia), fever, low red blood cell count (anemia), chills, upper respiratory tract infection, abdominal pain, diarrhea, rash, and headache. Other risks include an increased risk of infection and bleeding due to disruptions in the normal functioning of white blood cells, red blood cells, and clotting factors in the blood.


The exact mechanism of action of Bendamustine Injection is not yet fully understood, but researchers hope to gain further insight as more clinical trials are conducted. Despite its potentially harsh side effects, Bendamustine is a powerful and helpful adjunct to cancer therapies and can help patients manage their disease with less discomfort and fewer treatment cycles than traditional treatments. In some cases, Bendamustine may even be used as a first-line therapy.